TP53 Status and Estrogen Receptor-beta in Triple Negative Breast Cancer: Company matters
Menée in vitro et à l'aide d'échantillons tumoraux prélevés sur 354 patientes atteintes d'un cancer du sein triple négatif, cette étude analyse la corrélation entre le statut mutationnel du facteur de transcription TP53 et les effets pro- ou anti-carcinogènes du récepteur bêta aux estrogènes
Estrogen receptor
β (ESR2)shares a structural homology at the DNA and ligand binding domains (96% and 58%, respectively) with estrogen receptor α (ESR1), the major type ofestrogen receptor in breast cancer (1, 2).Similarities notwithstanding, ESR2has functionsand expression patternsdistinct from ESR1,and is widely expressed in both basal and luminal epithelial cells(3-6). The exact role of ESR2in breast cancer is not clear,with both anti-proliferative and proliferative roles being described(7, 8). The mechanisms for theseopposing
actions of ESR2in breast tumorigenesis have not been fully elucidated; this in part due todifferent isoforms and binding partners.
Journal of the National Cancer Institute , éditorial en libre accès, 2018